133 related articles for article (PubMed ID: 31077298)
21. Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs.
Al Hadidi S; Mims M; Miller-Chism CN; Kamble R
Ann Intern Med; 2020 Aug; 173(4):320-322. PubMed ID: 32568574
[No Abstract] [Full Text] [Related]
22. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development.
Khleif SN; Doroshow JH; Hait WN;
Clin Cancer Res; 2010 Jul; 16(13):3299-318. PubMed ID: 20501613
[TBL] [Abstract][Full Text] [Related]
23. Oncology's first Phase 0 trial.
Rowan K
J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322
[No Abstract] [Full Text] [Related]
24. Developing drugs that do not cause tumor regression.
Stadler W
Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
[No Abstract] [Full Text] [Related]
25. Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development.
Shea M; Ostermann L; Hohman R; Roberts S; Kozak M; Dull R; Allen J; Sigal E
Nat Rev Drug Discov; 2016 Mar; 15(3):152. PubMed ID: 26931085
[No Abstract] [Full Text] [Related]
26. Cancer drug approval in the United States, Europe, and Japan.
Milsted RA
Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
[No Abstract] [Full Text] [Related]
27. Can disease-free survival be a surrogate for overall survival for drug approvals?
Marwick C
J Natl Cancer Inst; 2004 Feb; 96(3):173. PubMed ID: 14759982
[No Abstract] [Full Text] [Related]
28. NCI seeks to speed drug development for pediatric cancers: New initiative aims to help prioritize agents with most potential.
Printz C
Cancer; 2016 Feb; 122(4):499-500. PubMed ID: 26844936
[No Abstract] [Full Text] [Related]
29. Researchers left to guess at outcomes of most cancer clinical trials.
Twombly R
J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
[No Abstract] [Full Text] [Related]
30. Food and Drug Administration requirements for approval of new anticancer drugs.
Johnson JR; Temple R
Cancer Treat Rep; 1985 Oct; 69(10):1155-9. PubMed ID: 4042094
[TBL] [Abstract][Full Text] [Related]
31. The Comparative Oncology Trials Consortium: using spontaneously occurring cancers in dogs to inform the cancer drug development pathway.
Gordon I; Paoloni M; Mazcko C; Khanna C
PLoS Med; 2009 Oct; 6(10):e1000161. PubMed ID: 19823573
[TBL] [Abstract][Full Text] [Related]
32. American Society of Clinical Oncology Developing First Clinical Trial.
Brower V
J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
[No Abstract] [Full Text] [Related]
33. More trials, fewer tribulations.
Eisenstein M
Sci Am; 2014 Jul; 311(1):S9-11. PubMed ID: 24974700
[No Abstract] [Full Text] [Related]
34. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
35. Unproven methods of cancer treatment: H.11.
CA Cancer J Clin; 1970; 20(3):172-5. PubMed ID: 4988623
[No Abstract] [Full Text] [Related]
36. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
[TBL] [Abstract][Full Text] [Related]
37. Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention.
Tuma R
J Natl Cancer Inst; 2008 Jun; 100(11):764-6. PubMed ID: 18505958
[No Abstract] [Full Text] [Related]
38. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Kluetz PG; Chingos DT; Basch EM; Mitchell SA
Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
[TBL] [Abstract][Full Text] [Related]
39. FDA approves sorafenib for patients with inoperable liver cancer.
Lang L
Gastroenterology; 2008 Feb; 134(2):379. PubMed ID: 18242200
[No Abstract] [Full Text] [Related]
40. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
